Home > All categories> Biochemicals and Pharmaceutical Chemicals> Pharmaceutical Impurities> ibrutinib

ibrutinib

Get Latest Price >

FOB Price contact us for price

Origin: China

Cas No: 936563-96-1

Specification: 99%min

Min order Quantity: 1 /kg

Supply Ability: 80 mt/month

Lead time: 7 days for OEM, 3 days for ready goods

Vendor:

Payment Terms:

Inquiry now

* Send an Inquiry to us

Add to wishlist

* Name your price
* Start order doesn't mean buying now

Products Specification
Product Description

Quick Details
CAS No.:
936563-96-1
Other Names:
N/A
MF:
C25H24N6O2
EINECS No.:
807-438-9
Place of Origin:
Hubei, China
Type:
Dyestuff Intermediates, Pharmaceutical Intermediates
Purity:
99%
Brand Name:
HHD
Application:
pharmaceutical intermediate, pharmaceutical raw material
Appearance:
white powder
Product Name:
Ibrutinib
CAS:
936563-96-1
Molecular formula:
C25H24N6O2
Molecular Weight:
440.5
Specification:
99%
Storage:
cool and dried place
Shelf life:
2 years
Packaging&Delivery
Port
shanghai port
Lead Time:
Quantity(Grams) 1 - 100 >100
Est. Time(days) 7 To be negotiated

Property

CAS No.: 936563-96-1 Formula: C25H24N6O2 Molecular Weight: 440.49700

Description

Ibrutinib (USAN, also known as PCI-32765 and marketed under the name Imbruvica) is an anticancer drug targeting B-cell malignancies. It is an orally-administered, selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase (BTK).
Ibrutinib was developed by Pharmacyclics, Inc and Johnson & Johnson's Janssen Pharmaceutical division for additional B-cell malignancies including diffuse large B-cell lymphoma and multiple myeloma.
It was approved by the US Food and Drug Administration (FDA) in November 2013 for the treatment of mantle cell lymphoma and in February 2014 for the treatment of chronic lymphocytic leukemia. In January 2015, ibrutinib was approved by the FDA for treatment of Waldenström's macroglobulinemia, a form of non-Hodgkin's lymphoma.
According to the Wall Street Journal in January 2016 ibrutinib, a specialty drug, cost US$116,600 to $155,400 a year wholesale in the United States. In spite of discounts and medical insurance, the prohibitive price causes some patients to not fill their prescriptions. The company marketing the drug, AbbVie, acquired it in May 2015, projecting global sales of US$1 billion in 2016 and $5 billion in 2020.

Basic Info

Chemical Name	ibrutinib
Synonyms	2-Propen-1-one, 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-;
CAS No.	936563-96-1
Molecular Formula	C25H24N6O2
Molecular Weight	440.49700
PSA	99.16000
LogP	4.73640